Terug
Ook genoteerd als
SMDPY
OTC
Dagbereik
€ 13,36
€ 14,29
52-Weeksbereik
€ 4,00
€ 19,20
Volume
801
50D / 200D Gem.
€ 14,11
/
€ 11,50
Vorige Slotkoers
€ 13,36
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,2 | 0,3 |
| P/B | 0,0 | 2,9 |
| ROE % | 14,5 | 3,7 |
| Net Margin % | 5,9 | 3,8 |
| Rev Growth 5Y % | -6,2 | 10,0 |
| D/E | 1,8 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 243,04
€ 219,63 – € 271,16
|
580 B | 1 |
| FY2029 |
€ 189,80
€ 171,51 – € 211,75
|
520 B | 1 |
| FY2028 |
€ 219,11
€ 198,00 – € 244,46
|
560 B | 1 |
Belangrijkste Punten
Revenue declined -6,23% annually over 5 years
ROE of 14,52% — decent returns on equity
Generating 3,47B in free cash flow
P/E of 0,22 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 33,02%
Capital efficient — spends only 3,27% of revenue on capex
Groei
Revenue Growth (5Y)
-6,23%
Revenue (1Y)26,79%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
14,52%
ROIC2,36%
Net Margin5,93%
Op. Margin3,74%
Veiligheid
Debt / Equity
1,80
Current Ratio1,05
Interest Coverage1,11
Waardering
P/E Ratio
0,22
P/B Ratio0,03
EV/EBITDA19,27
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 26,79% | Revenue Growth (3Y) | -15,27% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -6,23% | Earnings Growth (5Y) | -19,48% |
| Profitability | |||
| Revenue (TTM) | 398,83B | Net Income (TTM) | 23,63B |
| ROE | 14,52% | ROA | 3,18% |
| Gross Margin | 61,53% | Operating Margin | 3,74% |
| Net Margin | 5,93% | Free Cash Flow (TTM) | 3,47B |
| ROIC | 2,36% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1,80 | Current Ratio | 1,05 |
| Interest Coverage | 1,11 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 0,22 | P/B Ratio | 0,03 |
| P/S Ratio | 0,01 | PEG Ratio | -0,11 |
| EV/EBITDA | 19,27 | Dividend Yield | 0,00% |
| Market Cap | 5,31B | Enterprise Value | 287,61B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 398,83B | 314,56B | 555,54B | 560,04B | 515,95B |
| Net Income | 23,63B | -314,97B | -74,51B | 56,41B | 56,22B |
| EPS (Diluted) | 59,49 | -792,79 | -187,55 | 141,99 | 141,50 |
| Gross Profit | 245,40B | 187,98B | 376,63B | 402,91B | 378,18B |
| Operating Income | 14,93B | -354,86B | -76,98B | 60,23B | 71,22B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 742,60B | 907,51B | 1,13T | 1,31T | 1,31T |
| Total Liabilities | 573,13B | 751,37B | 727,96B | 634,44B | 659,95B |
| Shareholders' Equity | 169,48B | 156,06B | 406,75B | 607,89B | 580,57B |
| Total Debt | 305,42B | 427,86B | 334,72B | 269,05B | 273,82B |
| Cash & Equivalents | 23,12B | 29,05B | 143,48B | 202,98B | 193,70B |
| Current Assets | 253,17B | 269,57B | 381,86B | 499,52B | 459,80B |
| Current Liabilities | 240,60B | 515,47B | 372,69B | 278,37B | 278,15B |